170 products were found matching "K06619"!

c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. It is implicated in regulating cell proliferation, apoptosis, differentiation, cell adhesion, and stress responses. Protein function: Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and...

Abl substrate peptide is a peptide substrate for the tyrosine kinase Abl. It is selectively phosphorylated by Abl over c-Src kinase at 20 µM. Abl substrate peptide has been used to quantify Abl kinase activity in vitro.Formal Name:...

Dasatinib is a potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family. It is effective at sub-nanomolar concentrations, inhibiting Src, Abl, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively. At nanomolar concentrations, dasatinib also blocks the...

Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases. Saracatinib is orally available and blocks cell motility, migration, adhesion,...

Soluble in DMSO at 200 mg/mL, very poorly soluble in ethanol, very poorly soluble in water, maximum solubility in plain water is estimated to be about 10 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility

Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively). It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others. Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to...

Active human Abelson murine leukemia viral oncogene homolog 1 (Abl-1) (GenBank Accession No. NM_007313), amino acids 248-531, with N-terminal His-tag, MW = 33 kDa, expressed in a Baculovirus-infected Sf9 cell expression system.

GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells...

Asciminib is an allosteric inhibitor of Abl1 (IC50 = 0.45 nM). It is selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 µM), as well as ion channels, nuclear receptors, G protein-coupled receptors (GPCRs), and transporters. Asciminib inhibits the proliferation of Luc-Ba/F3 cells...

Bcr-Abl, a fusion protein with deregulated tyrosine kinase activity, is highly expressed in chronic myelogenous leukemia (CML). Bafetinib is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib (Cay-13139), with modifications added to improve binding and potency against...

Rebastinib is an orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM) as well as the gatekeeper mutant Abl1T315I (IC50 = 4 nM) and the activation loop mutant Abl1H396P. It also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar...

PD 166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC50 = 8 nM) and Bcr/Abl-dependent cell growth (IC50 = 0.4 nM). In addition to targeting a select group of receptor tyrosine kinases, PD 166326 also potently inhibits c-src (IC50 = 6 nM). Orally administered PD 166326 is...